Evolving role of immunotherapy in the treatment of refractory warts

Devinder M Thappa, Minu J Chiramel

ABSTRACT

Cutaneous and genital warts are common dermatological conditions caused by the human papilloma virus (HPV). Although it is a benign condition, it causes disfigurement, has a tendency to koebnerize, and can be transmitted to others. This makes adequate and timely treatment important. There are several conventional treatments available with variable response. Topical and systemic immunotherapy has now found a significant place in the treatment of warts because of its nondestructive action, ease of use, and promising results. Through this review, we would like to present a brief overview of the various immunotherapeutic agents used. These include more established agents such as imiquimod, Mycobacterium w vaccine, bacillus Calmette-Guérin vaccine, measles, mumps, and rubella vaccine, Candida antigen, trichophyton antigen, tuberculin, zinc, cimetidine, levamisole, HPV vaccine, and autoimplantation therapy. Other agents such as contact immunotherapy which is sparsely used now than before and newer agents such as Corynebacterium parvum, sinecatechins, echinacea, propolis, glycyrrizinic acid, and Vitamin D have also been discussed. The mechanism of action of these agents, along with their dosage, mode of administration, duration of use, expected outcomes and comparative efficacy, evidence for their use, and expected side effects, if any, are reviewed.

Keywords: Cutaneous, genital, immunotherapy, verruca, wart

INTRODUCTION

Immunotherapy is defined as a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection, and other diseases. Some types of immunotherapy only target certain cells of the immune system. Others affect the immune system in general. Types of immunotherapy include cytokines, vaccines, and some monoclonal antibodies. It may either be an activation immunotherapy, where immunity is induced or enhanced (used in infections, cancers), or a suppression immunotherapy, where immunity is suppressed (used in autoimmune diseases). The use of immunotherapy is well-established in malignancies and has now found a role in infections as well.

Human papilloma virus (HPV) is a small DNA virus, which is implicated in benign and malignant neoplasia.[1] Cutaneous and genital warts constitute the benign end of the spectrum, and their management still continues to annoy dermatologists. Although the spontaneous resolution rate for warts is 65–78%, the cosmetic disfigurement, tendency to spread, and associated poor quality of life warrants quick intervention.[2] The conventional modalities in treatment of warts include destructive therapies such as salicylic acid, trichloroacetic acid, cryotherapy, silver nitrate, phenol, canthiridin, surgical interventions and lasers; antiproliferative agents such as bleomycin, vitamin D analogs, podophyllin, podophyllotoxin, and 5-fluoro uracil; antiviral agents such as cidofovir and retinoids.[3] Because of the cumbersome nature of these procedures and a high risk of recurrence, immunotherapy is becoming more and more popular, especially in the treatment of refractory cutaneous and...
When to consider immunotherapy

There are no well-defined criteria or consensus on when immunotherapy should be tried in a patient with warts. Current indications include:

1. Recalcitrant warts
2. Recurrent warts
3. Extensive warts
4. Difficult to treat areas—periungual and palmoplantar sites

The various agents used with the indications, dosage and route of administration are mentioned in Table 1. Individual agents are discussed below.

Imiquimod

Imiquimod is a non-nucleoside heterocyclic amine which acts as an immune response modifier. It increases the cellular levels of interferon alpha (IFN-α), tumor necrosis factor alpha (TNF-α), and interleukin-6 (IL-6), which leads to strong antiviral and antitumor effects. Arany et al. showed that high constitutive levels of signal transducer and activator of transcription 1 (STAT1) and interferon response factor 1 (IRF1) but low levels of IRF2 and protein inhibitor of activated STAT1 (PIAS1) are essential for a complete response to imiquimod therapy. In a multicentric, double-blind, randomized controlled trial by Beutner et al., 5% imiquimod cream was more effective than 1% in treatment of genital warts when applied at home by the patient as a thrice-a-week application for 16 weeks. A systematic review by Moore et al. in 2001 concluded that imiquimod is an effective home-based treatment modality for genital warts. There was complete resolution of warts in up to 76% of the patients. The efficacy of imiquimod has been studied in cutaneous warts as well, with 27–89% in immunocompetent and 33–50% in immunocompromised showing complete response. The commonly reported side effects include burning sensation, pain, erythema, and vitiligo-like depigmentation. It is found to be effective and safe in children and there are reports of safe use in pregnancy.

The high cost of medication and difficulty in obtaining the medication in India poses problems in the widespread use of imiquimod. There were also some concerns raised in a Cochrane review in 2014, which showed a high number of industry sponsored studies regarding the efficacy of imiquimod.

Mycobacterium w

*Mycobacterium indicus pranii* or *Mycobacterium w* is a rapid growing nontubercular mycobacteria, which has been found to induce a strong proinflammatory response while injected

| Table 1: Various agents used in immunotherapy of warts |
|---|
| **Agents** | **Indication, dosage and administration** |
| **Topical agents** | | |
| Imiquimod | For genital and cutaneous warts, 5% cream, 3 times a week, for 16 weeks |
| Sinecatechins | For cutaneous warts, 10% ointment 3 times a day for maximum 16 weeks |
| BCG | For cutaneous and genital warts, applied topically on the warts in normal saline or salicylic acid, washed after 2 hours, weekly treatment for 6 to 12 weeks |
| **Intralesional (IL) agents** | | |
| Mw vaccine | For cutaneous warts, 0.1 ml intradermal into 3-5 warts or all warts, followed by 0.1 ml intralesional, 2-4 weekly, maximum 10 sittings |
| BCG vaccine | For cutaneous and genital warts, 0.1-0.5 ml intralesional injection in largest wart, in 2 weeks interval in 5 sittings. |
| PPD | For genital warts, 0.1 ml weekly intradermal injection in the forearm for 12 weeks |
| MMR vaccine | For cutaneous warts, 0.3-0.5 ml into single largest wart fortnightly for up to 5 sittings |
| Candidial extract | For cutaneous warts, 0.1-0.3 ml injected into the largest wart at first sitting, then 3 weekly intralesional injections |
| Trichophyton antigen | For cutaneous and genital warts, 0.3 ml injected into largest wart every 3 weeks, maximum of 5 sittings |
| Tuberculin | For cutaneous warts, 2.5 units into few warts every 2 weekly |
| Vitamin D3 | For cutaneous warts, 0.2 ml of 7.5 mg/ml, Vitamin D intralesional, 2 sessions 4 week apart |
| Interferon alpha 2B | For genital warts, 1-2 million units 3 days/week (Monday-Wednesday-Friday) for 3 weeks |
| **Systemic** | | |
| Zinc | For cutaneous warts, 10mg/kg/day (2.5 mg/kg/day elemental zinc) for 2 months |
| Cimetidine | For cutaneous warts, 20-40 mg/kg/day for 3-4 months |
| Levamisole | For cutaneous warts, 2.5-5 mg/kg/day, 2-3 consecutive days every 2 weeks for 4-5 months. |
| Echinacea | For cutaneous warts, 600 mg single oral dose (single study) |
| Propolis | For cutaneous warts, 500 mg single oral dose (single study) |
| HPV vaccines | For cutaneous warts, 0.5 ml intramuscularly, at 0, 2 and 6 months (2 dose or 3 dose regimen) may be followed |
intraleisonally. There is a prominent delayed hypersensitivity response with an increase in T helper 1 cytokines such as IL-2, IL-4, IL-6, and IFN gamma and activation of natural killer cells and cytotoxic T cells. The HPV laden cells are caught in the crossfire leading to clearance of warts both at the site of injection and distally.\cite{2,12} It is administered in two ways—either with an intradermal sensitizing dose or without it. In the first method, a sensitizing dose of 0.1 ml is administered intradermally in the deltoid region followed by 2–4 weekly intralesional injections in few warts (maximum 0.1 ml in each sitting) for up to 10 sittings. In the latter, the sensitization dose is missed and direct intralesional injections are started.\cite{2,12} The response varied by 54–93% in cutaneous warts and 89% in genital warts.\cite{2,12,13-14} In an open label comparative study involving 66 patients with extragenital warts by Dhakar \textit{et al.}, complete clearance of treated warts was seen in 66.7% (20/30) and 65.5% (19/29) of the patients in the Mycobacterium w (Mw) and cryotherapy groups, respectively. Clearance of distant warts was significantly high (P = 0.004) high in the Mw group. Improvement in the Dermatology Life Quality Index was greater in the Mw group.\cite{15} In a double-blind randomized control trial by Kumar \textit{et al.} involving 89 patients of genital warts comparing Mw vaccine with 5% imiquimod cream, 67% of patients in the Mw group and 59% in the imiquimod group showed complete resolution. (P = 0.5, nonsignificant difference).\cite{16} In another open label study in multiple extragenital warts by Meena \textit{et al.} in 40 patients, 83% showed complete resolution.\cite{17} The reported side effects include pain, nodularity, ulceration, scarring at the site of injection, flu-like symptoms, fever, and lymphadenopathy.\cite{18} Paraesthesia on the limb distal to the site of injection have also been reported.\cite{19}

**Bacillus Calmette-Guérin vaccine**

The principle behind using Bacillus Calmette-Guérin (BCG) vaccine is the same as that of the Mw vaccine. The delayed hypersensitivity response against the antigen is the key to clinical response against warts. It increases the serum levels of IL-12 and decreases the level of IL-4.\cite{18} One to three doses are administered 1 month apart. In a single-blind placebo-controlled trial by Sharique \textit{et al.} involving 154 patients of cutaneous warts (common, plantar and plane warts), there was 39.7% resolution with BCG vs. 13.7% with placebo.\cite{19} In another placebo controlled trial (n = 80), topically applied BCG paste (weekly for 6 weeks) has also been found to be effective in children with common warts and plane warts with 65% and 45% resolution, respectively.\cite{20} No side effects were reported in these two studies. However, another report by Daulatabad \textit{et al.} in 7 patients from India showed a high incidence of flu-like symptoms precluding further doses in 57% patients, making one question its safety in tuberculosis endemic countries like India.\cite{21}

**Measles, mumps, rubella vaccine**

Measles, mumps, rubella (MMR) viral vaccine accelerates the clearance of virus and viral infected cells by stimulation of cell-mediated and humoral immunity.\cite{22} It has been used in a dose of 0.5 ml injected into each cutaneous wart once in two weeks for up to 5 sittings to produce 63% complete resolution by Nofal \textit{et al.} Pain, itching, erythema, and flu-like symptoms were the side effects noted.\cite{23} Another study by Na \textit{et al.} involving 136 patients of cutaneous warts showed more than half reduction in the size of wart in 51% patients whereas only 5.6% had complete resolution.\cite{24} Pain at the site of injection was the only adverse effect noted. Eighty seven percent complete resolution was noted in 40 patients with multiple plantar warts within 3 sittings by Gamil \textit{et al.}\cite{25} In a study by Shaheen \textit{et al.}, comparing MMR vaccine with intralesional purified protein derivative and saline in 10 patients each, the rate of lesional and distal resolution were 60% each with purified protein derivative (PPD) and 80% and 40% with MMR and 0% with saline.\cite{26}

**Candida antigen**

\textit{Candida albicans} extract is injected intralesionally to provoke a cellular response and clearance of warts. 0.3 ml candida extract is injected into the largest wart at first visit and consequently every 3 weeks. Distal clearance was seen in 82% of patients in a phase 1 trial in 18 patients suffering from cutaneous warts by Kim \textit{et al.} Immune response to HPV-57 L1-peptide (380-412) was most commonly seen.\cite{27} In 220 children treated by Munoz Garza \textit{et al.}, a 71% complete resolution of the injected wart was noticed with an average of 2.7 sittings of intralesional candida. Distant response was seen in 21% patients with only half showing a complete response.\cite{28} Other studies showed a 39–87% complete response with or without adjuvant treatment.\cite{29-31} Three out of 7 human immunodeficiency virus (HIV) positive patients showed clearance of warts when treated with this modality.\cite{28} The most common side effect was pain and discomfort during injection, however, serious side effects such as vitiligo-like depigmentation and painful purple digit have also been reported.\cite{32} Another rare side effect described by Signore \textit{et al.} is post-immunotherapy revealed cicatrix (PIRC). This refers to the scar of previous destructive procedures tried on a wart that becomes visible once immunotherapy starts working and the wart starts healing. The scar should not be wrongly attributed to the immunotherapy per se.

**Trichophyton skin antigen**

\textit{Trichophyton} antigen has been prepared as an allergic extract from \textit{Trichophyton} species by adding extracting solution. Horn \textit{et al.} in a randomized controlled single blind study found that 62% patients with cutaneous warts responded to intralesional trichophyton injections (0.3 ml every 3 weeks, maximum of 5 sittings) and the response was not statistically different from the response to mumps antigen and candida antigen, with or without IFN alpha added to it.\cite{33} There is a dearth of studies with trichophyton as a single agent. It has been useful in combination with candida and mumps antigen, and the combination of all...
three antigens has been reported to have a 71% response rate which was significantly better than individual agents.\(^{35,36}\)

**Tuberculin**

PPD or tuberculin stimulates the cell-mediated immunity nonspecifically by activating Th1 cells, NK cells, and cytokine production. An increase in IL-12 as a process in boosting the cell-mediated immunity contributes to the mechanism of action.\(^{37}\) It has been injected intradermally into difficult to treat cutaneous warts (palmar plantar warts, periungual warts, facial warts (>10 lesions), verruca vulgaris (>10 lesions) and verruca plana (>10 lesions) at a dose of 2.5 units into few warts every 2 weeks by Saoji et al. to produce 76% complete resolution at the end of 4 injections. Over a 6-month follow-up, only one recurrence was noticed. Side effects were mild and included erythema, edema, and pain.\(^{38}\)

**Interferons**

Interferons are natural small proteins that play an in-vivo role in viral interference. Therapeutically, IFNα-2B has been used for its immunomodulatory, antiviral, and antiproliferative properties. There are conflicting reports on its efficacy in warts. In a systematic review, 12 randomized controlled trials with 1445 patients showed that there was a significant difference in the response rate of genital warts between treatment with topical interferons and placebo (44.4% vs 16.1%). However, there was no significant difference in response between systemic interferons and placebo (27.4% vs 26.4%). The rate of relapse was also less with topical interferons.\(^{39}\) Flu-like symptoms have been reported as a possible side effect. Horn et al. conducted a single-blind, randomized controlled trial in 233 patients with one or more cutaneous warts and found that there was no added benefit of combining IFNα2a or IFNα2b to candid antigen, trichophyton antigen, or mumps antigen.\(^{40}\)

**Zinc**

Zinc is important for immune regulation and stimulates the leucocytes and natural killer cells. Both oral and topical zinc has been found to be useful in the treatment of cutaneous and genital warts. It has been shown that there is a deficiency of zinc in patients with multiple or recurrent warts.\(^{40,41}\) Oral zinc sulphate given in a dose of 10 mg/kg/day has been used, with approximately 84–87% patients showing complete resolution of warts in 2 months in two randomized placebo-controlled trials.\(^{42,43}\) It has been used as a single agent as well as in combination with other modalities such as imiquimod, podophyllin, and cryotherapy.\(^{44}\) It has been found to be more effective than cimetidine.\(^{45}\) Topical 5% and 10% zinc solution has been used in cutaneous warts, 3 times a day for 4 weeks with only 5% and 11% response, respectively.\(^{46}\) Topical zinc oxide 20% ointment showed almost similar efficacy as salicylic acid–lactic acid combination.\(^{47}\)

**H2 receptor blockers**

H2 blockers, such as cimetidine and ranitidine, have been tried in treatment of warts. They block the type 2 histamine receptors on suppressor T cells and augments cell-mediated immunity. It increases mitogen-induced lymphocyte proliferation and inhibits suppressor T cells.\(^{48}\) It increases the levels of IFNγ and IL-2 and decreases the levels of IL-18.\(^{49}\) It has been used in a dose of 20–40 mg/kg/day for 3–4 months with response ranging from 30–87%.\(^{50,51}\) Side effects were mild and included nausea, vomiting, and headache. There are only preliminary studies using ranitidine with doubtful efficacy.\(^{52}\) Other double blind studies, however, show conflicting reports of minimal-to-no response especially to low dose cimetidine.\(^{53,54}\) Safety and a slightly better efficacy in children than adults is reported.\(^{55}\) It was also shown to be more effective when used in combination with levamisole.\(^{56}\)

A systematic review in 2007 concluded that there is insufficient evidence for efficacy of cimetidine and ranitidine in viral warts.\(^{57}\)

**Levamisole**

Levamisole was introduced as an anthelminthic agent but was soon found to have immunomodulatory effects, making it effective in various dermatological disorders. It has been used in treatment of cutaneous warts at a dose of 2.5–5 mg/kg/day for 3 consecutive days every 2 weeks for 4–5 months.\(^{58-60}\) The response to levamisole was approximately 60%. However, in a double blind study by Schou et al., no difference was seen between levamisole 150 mg/day for 3 days every alternate week and placebo.\(^{61}\) Levamisole can cause rash, nausea, abdominal cramps, taste alteration, alopecia, arthralgia, and a flu-like syndrome but rarely causes myopathy, leucocytoclastic vasculitis, lichenoid eruptions, and leukoencephalopathy.\(^{58,62}\)

**Human papilloma virus vaccines**

The quadrivalent HPV vaccine that comprises the L1 protein of HPV types 6, 11, 16, and 18 has been in use on a large scale in countries like Denmark with a decline in the prevalence of genital warts. The risk of warts decreased with each dose of HPV vaccine. Patients who received 3 doses had complete protection from genital warts whereas, in those receiving 2 doses, increase in interval between the 2 doses led to a further decline in genital wart incidence.\(^{63}\) Similar decline in genital warts has been noticed in the UK and Australia.\(^{64,65}\)

There are also reports of HPV vaccine being used in patients with cutaneous warts which has led to resolution of warts, both in immunocompetent and immunocompromised individuals.\(^{66,67}\) Now, with the development of nonavalent HPV vaccine against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, a further decline in HPV-related diseases including warts is expected.\(^{68}\)

**Autoimplantation therapy**

The concept of autoimplantation is that the cell-mediated immunity that is oblivious to the HPV infection is stimulated by
Thappa and Chiramel: Immunotherapy in the treatment of refractory warts

introducing a higher load of the same antigens at a location where a strong immune system activation can occur. Full thickness excision of one wart is made, and after mincing it, the particles are introduced into a dermal pocket. Flexor aspect of the left forearm approximately 2 inches below the antecubital fossa is the usual site of autoimplantation. In a study by Shiva Kumar et al. involving 60 patients, 73.3% total clearance of warts was noticed, with a majority of them (91%) within 2 months. In a modification of this procedure in palmoplantar warts, the pared wart tissue was introduced into the subcutis using a single stab incision and 74.1% resolution was noticed. Post-inflammatory hypopigmentation and formation of an inflammatory nodule at the site of implantation are the potential side effects.

CONCLUSION

There are many agents used for immunotherapy which show significant results in terms of safety and efficacy. There is always an issue that the tendency for spontaneous resolution in warts may cause a false increase in treatment response that can be attributed to each agent. When to opt for immunotherapy and which agent to use, still remains unanswered. This issue needs to be addressed on a patient-to-patient basis after considering factors such as disease burden, availability of medication, cost of therapy, potential side effects, and immune status of the patient. Combination of immunotherapy with other destructive modalities such as cryotherapy and radiofrequency ablation or concomitant use of multiple modalities of immunotherapy has shown to enhance the treatment response, however, further studies are needed in this area.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Santos-López G, Márquez-Domínguez L, Reyes-Leyva J, Vallejo-Ruiz V. General aspects of structure, classification and replication of human papillomavirus. Rev Médica Inst Mex Seguro Soc 2015;53(Suppl 2):S166-71.
2. Singh S, Chouhan K, Gupta S. Intralesional immunotherapy with killed Mycobacterium indicus pranii vaccine for the treatment of extensive cutaneous warts. Indian J Dermatol Venereol Leprol 2014;80:509-14.
3. Sterling JC, Gibbs S, Haque Hussain SS, Mohd Mustapa MF, Handfield-Jones SE. British Association of Dermatologists’ guidelines for the management of cutaneous warts 2014. Br J Dermatol 2014;171:696-712.
4. Beutner KR, Tyring SK, Trofatter KF, Douglas JM, Spruance S, Owens ML, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998;42:789-94.
5. Arany I, Tyring SK, Brysk MM, Stanley MA, Tomai MA, Miller RL, et al. Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (imiquimod) in genital warts. Antimicrob Agents Chemother 2000;44:1869-73.
6. Perry CM, Lamb HM. Topical imiquimod: A review of its use in genital warts. Drugs 1999;58:375-90.
7. Moore RA, Edwards JE, Hopwood J, Hicks D. Imiquimod for the treatment of genital warts: A quantitative systematic review. BMC Infect Dis 2001;1:3.
8. Ahn CS, Huang WW. Imiquimod in the treatment of cutaneous warts: An evidence-based review. Am J Clin Dermatol 2014;15:387-99.
9. Stefanaki C, Lagogiani I, Kouris A, Kontochristopoulos G, Antoniou C, Katzarou A. Cryotherapy versus imiquimod 5% cream combined with a keratolytic lotion in cutaneous warts in children: A randomized study. J Dermatol Treat 2016;27:80-2.
10. Ciavattini A, Tsiroglou D, Vichi M, Di Giuseppe J, Cecchi S, Tranquilli AL. Topical Imiquimod 5% cream therapy for external anogenital warts in pregnant women: Report of four cases and review of the literature. J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet 2012;25:873-6.
11. Grillo-Ardila CF, Angel-Müller E, Salazar-Díaz LC, Gaitán HG, Ruiz-Parra AI, Lethaby A. Imiquimod for anogenital warts in...
non-immunocompromised adults. Cochrane Database Syst Rev 2014;11:CD010389.
12. Garg S, Baveja S. Intrallesional immunotherapy for difficult to treat warts with Mycobacterium w vaccine. J Cutan Aesthetic Surg 2014;7:203-8.
13. Gupta S, Malhotra AK, Verma KK, Sharma VK. Intrallesional immunotherapy with killed Mycobacterium w vaccine for the treatment of geno-cutaneous warts: An open label pilot study. J Eur Acad Dermatol Venereol JEADV 2008;22:1089-93.
14. Meena JK, Malhotra AK, Mathur DK, Mathur DC. Intrallesional immunotherapy with mycobacteriumw vaccine in patients with multiple cutaneous warts: Uncontrolled open study. JAMA Dermatol 2013;149:237-9.
15. Dhakar AK, Dogra S, Vinay K, Sarangal R, Kanwar AJ, Singh MP. Intrallesional Mycobacterium w vaccine versus cryotherapy in treatment of refractory genital warts: A randomized, open-label, comparative Study. J Cutan Med Surg 2016;20:123-9.
16. Kumar P, Dar L, Saldiwal S, Varma S, Datt Upadhyay A, Talwar D, et al. Intrallesional injection of Mycobacterium w vaccine vs imiquimod, 5%, cream in patients with anogenital warts: Randomized clinical trial. JAMA Dermatol 2014;150:1072-8.
17. Singh S, Chouhan K, Gupta S. Intrallesional immunotherapy with killed Mycobacterium indicus pranii vaccine for the treatment of extensive cutaneous warts. Indian J Dermatol Venereol Leprol 2014;80:509-14.
18. Zuo C, Huang J, Liao Z, Lu J, Chen J. Effects of BCG-PSN on serum levels of IL-4 and IL-12 in patients with condyloma acuminatum. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2004;29:690-2.
19. Sharquie KE, Al-Rawi JR, Al-Nuaimy AA, Radhy SH. Bacille Calmette-Guerin immunotherapy for viral warts. Saudi Med J 2008;29:589-93.
20. Salem A, Nofal A, Hosny D. Treatment of common and plane warts in children with topical viable Bacillus Calmette-Guerin. Pediatr Dermatol 2013;30:60-3.
21. Daulatabad D, Pandhi D, Singal A. BCG vaccine for immunotherapy in warts: Is it really safe in a tuberculosis endemic area? Dermatol Ther 2016;29:168-72.
22. Zamanian A, Mobasher P, Jazi GA. Efficacy of intrallesional injection of mumps-measles-rubella vaccine in patients with wart. Adv Biomed Res 2014;3:107.
23. Nofal A, Nofal E, Yosef A, Nofal H. Treatment of recalcitrant warts with intrallesional measles, mumps, and rubella vaccine: A promising approach. Int J Dermatol 2015;54:667-71.
24. Na CH, Choi H, Song SH, Kim MS, Shin BS. Two-year experience of using the measles, mumps and rubella vaccine as intrallesional immunotherapy for warts. Clin Exp Dermatol 2014;39:583-9.
25. Gamli H, Elgharib I, Nofal A, Abd-Elaziz T. Intrallesional immunotherapy of plantar warts: Report of a new antigen combination. J Am Acad Dermatol 2010;63:40-3.
26. Shaheen MA, Salem SAM, Fouad DA, El-Fatah AAA. Intrallesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: A comparative clinical and immunological study. Dermatol Ther 2015;28:194-200.
27. Khim KH, Horn TD, Pharis J, Kincannon J, Jones R, O’Bryan K, et al. Phase I clinical trial of intrallesional injection of candida antigen for the treatment of warts. Arch Dermatol 2010;146:1431-3.
28. Muñoz Garza FZ, Roč Crespo E, Torres Pradilla M, Aguiler Petró P, Baltá Cruz S, Hernández Ruiz ME, et al. Intrallesional Candida antigen immunotherapy for the treatment of recalcitrant and multiple warts in children. Pediatr Dermatol 2015;32:797-801.
29. Ali Khan A, Griffin JR, Newman CC. Use of Candida antigen injections for the treatment of verruca vulgaris: A two-year mayo clinic experience. J Dermatol Treat 2015;1-4.
30. Maron M, Salm C, Lyon V, Galbraith S. One-year experience with candida antigen immunotherapy for warts and molluscum. Pediatr Dermatol 2008;25:189-92.
31. Majid I, Imran S. Immunotherapy with intrallesional Candida albicans antigen in resistant or recurrent warts: A study. Indian J Dermatol 2013;58:360-5.
32. Wong A, Crawford RL. Intrallesional Candida antigen for common warts in people with HIV. J Cutan Med Surg 2013;17:313-5.
33. Perman M, Sterling JB, Gaspari A. The painful purple digit: An alarming complication of Candida albicans antigen treatment of recalcitrant warts. Dermat Contact Atopic Derm 2005;16:38-40.
34. Horn TD, Johnson SM, Helm RM, Roberson PK. Intrallesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: A single-Blinded, randomized, and controlled trial. Arch Dermatol 2005;141:589-94.
35. Johnson SM, Horn TD. Intrallesional immunotherapy for warts using a combination of skin test antigens: An effective and effective therapy. J Drugs Dermatol JDD 2004;3:263-5.
36. Al-dahhan AS, Mlaeker S, Shah VV, Kamath P, Alsaídah M, Samarkandy S, et al. Efficacy of intrallesional immunotherapy for the treatment of warts: A review of the literature. Dermatol Ther 2016;29:197-207.
37. Abd-Elazim MFA, Mohammed GFA, Fathy A, Mohamed RW. Evaluation of IL-12 serum level in patients with recalcitrant multiple common warts, treated by intrallesional tuberculin antigen. J Dermatol Treat 2014;25:264-7.
38. Soajo V, Lade NR, Gadegone R, Bhat A. Immunotherapy using purified protein derivative in the treatment of warts: An open uncontrolled trial. Indian J Dermatol Venereol Leprol 2016;82:42-6.
39. Yang J, Yu P, Zeng Z, Yu Z, Huang N, Deng Q. Interferon for the treatment of genital warts: A systematic review. BMC Infect Dis 2009;9:156.
40. Raza N, Khan DA. Zinc deficiency in patients with persistent viral warts. J Coll Physicians Surg Pak JCPSP 2010;20:83-6.
41. López-García DR, Gómez-Flores M, Arce-Mendoza AY, de la Fuente-García A, Ocampo-Candiani J. Oral zinc salt for unresponsive cutaneous viral warts: Too good to be true? A double-blind, randomized, placebo-controlled trial. Clin Exp Dermatol 2009;34:e984-5.
42. Al-Gurairi FT, Al-Waiz M, Sharquie KE. Oral zinc sulphate in the treatment of recalcitrant viral warts: Randomized placebo-controlled clinical trial. Br J Dermatol 2002;146:423-31.
43. Mun JH, Kim SH, Jung DS, Ko HC, Kim BS, Kwon KS, et al. Oral zinc sulphate treatment for viral warts: An open-label study. J Dermatol 2011;38:541-5.
44. Akhavan S, Mohammad SR, Modarres Gillani M, Mousavi AS, Shirazi M. Efficacy of combination therapy of oral zinc sulfate with imiquimod, podophyllin or cryotherapy in the treatment of vulvar warts. J Obstet Gynaecol Res 2014;40:2110-3.
45. Stefani M, Bottino G, Fontenelle E, Azulay DR. Efficacy comparison between cimetidine and zinc sulphate in the treatment of multiple and recalcitrant warts. An Bras Dermatol 2009;84:23-9.
46. Sharquie KE, Khorsheed AA, Al-Nuaimy AA. Topical zinc sulphate solution for treatment of viral warts. Saudi Med J 2007;28:1418-21.
47. Khattar JA, Musharrafieh UM, Tamim H, Hamadeh GN. Topical zinc oxide vs. salicylic acid-lactic acid combination in the treatment of warts. J Obstet Gynaecol Res 2014;40:2110-3.
48. Paller AS. Cimetidine for the treatment of warts. West J Med 1996;164:520-1.
49. Mitsuishi T, Iida K, Kawana S. Cimetidine treatment for viral warts enhances IL-2 and IFN-gamma expression but not IL-18 expression in lesional skin. Eur J Dermatol 2003;13:445-8.
50. Goopu C, Higgins CR, James MP. Treatment of viral warts with cimetidine: An open-label study. Clin Exp Dermatol 2000;25:183-5.
51. Yilmaz E, Alpsoy E, Basaran E. Cimetidine therapy for warts: A placebo-controlled, double-blind study. J Am Acad Dermatol 1996;34:1005-7.
52. Karaman G, Sendur N, Sevk E. Ranitidine therapy for recalcitrant warts: A randomized controlled study. J Cutan Med Surg 2016;20:123-9.
53. Sáenz-Santamaría MC, Gilaberte Y. Cimetidine and warts. Arch Dermatol 1997;133:530-1.
54. Lee SH, Rose B, Thompson CH, Cossart Y. Plantar warts of defined aetiology in adults and unresponsiveness to low dose cimetidine. Australas J Dermatol 2001;42:220-1.
55. Rogers CI, Gibney MD, Siegfried EC, Harrison BR, Glaser DA. Cimetidine therapy for recalcitrant warts in adults: Is it any better than placebo? J Am Acad Dermatol 1999;41:123-7.
56. Parsad D, Pandhi R, Juneja A, Negi KS. Cimetidine and levamisole versus cimetidine alone for recalcitrant warts in children. Pediatr Dermatol 2001;18:349-52.
57. Fit KE, Williams PC. Use of histamine2-antagonists for the treatment of verruca vulgaris. Ann Pharmacother 2007;41:1222-6.
58. Amer M, Tosson Z, Soliman A, Selim AG, Salem A, al-Gendy AA. Verrucae treated by levamisole. Int J Dermatol 1991;30:738-40.
59. Moncada B, Rodriguez ML. Levamisole therapy for multiple warts. Br J Dermatol 1979;101:327-30.
60. Saúl A, Sanz R, Gomez M. Treatment of multiple viral warts with levamisole. Int J Dermatol 1980;19:342-3.
61. Schou M, Helin P. Levamisole in a double-blind study: No effect on warts. Acta Derm Venereol 1977;57:449-54.
62. Scheinfeld N, Rosenberg JD, Weinberg JM. Levamisole in dermatology: A review. Am J Clin Dermatol 2004;5:97-104.
63. Blomberg M, Dehlendorf FC, Sand C, Kjaer SK. Dose-related differences in effectiveness of human papillomavirus vaccination against genital warts: A nationwide study of 550,000 young girls. Clin Infect Dis 2015;61:676-82.
64. Clarke E, Board C, Patel N, Atkinson L, Tulloch H, Patel R. Why are anogenital warts diagnoses decreasing in the U.K.? Bivalent human papillomavirus (HPV) vaccine cross-protection or failure to examine? Sex Transm Infect 2014;90:587.
65. Chow EP, Read TR, Wigan R, Donovan B, Chen MY, Bradshaw CS, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2015;91:214-9.
66. Venugopal SS, Murrell DF. Recalcitrant cutaneous warts treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, and 18) in a developmentally delayed, 31-year-old white man. Arch Dermatol 2010;146:475-7.
67. Silling S, Wieland U, Werner M, Pfister H, Potthoff A, Kreuter A. Resolution of novel human papillomavirus–induced warts after HPV vaccination. Emerg Infect Dis 2014;20:142-5.
68. Riethmuller D, Jacquard AC, Laca St Guily J, Aubin F, Carcopino X, Pradat P, et al. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. BMC Public Health [Internet] 2015 [cited 2016 Mar 1];15. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433025
69. Shivakumar V, Okade R, Rajkumar V. Autoimplantation therapy for multiple warts. Indian J Dermatol Venereol Leprol 2009;75:593-5.
70. Nischal KC, Sovmya CS, Swaroop MR, Agrawal DP, Basavaraj HB, Sathyarayana BD. A novel modification of the autoimplantation therapy for the treatment of multiple, recurrent and palmoplantar warts. J Cutan Aesthetic Surg 2012;5:26-9.
71. Word AP, Nezafati KA, Cruz PD Jr. Treatment of warts with contact allergens. Dermatitis 2015;26:32-7.
72. Sljivić VS, Watson SR. The adjuvant effect of Corynebacterium parvum: T-cell dependence of macrophage activation. J Exp Med 1977;145:45-57.
73. Nasser N. Treatment of common warts with the immune stimulant Propionium bacterium parvum. An Bras Dermatol 2012;87:585-9.
74. Zedan H, Hofny ERM, Ismail SA. Propolis as an alternative treatment for cutaneous warts. Int J Dermatol 2009;48:1246-9.
75. Gupta AK, Daigle D. Sincatechins 10% ointment: Agreen tea extract for the treatment of external genital warts. Skin Ther Lett 2015;20:6-8.
76. Dominguez Gómez J, Simón RD, Abreu Daniel A, Zelenkova H. Effectiveness of Glycyrrhizinic Acid (Glizigen) and an Immunostimulant (Viussid) to Treat Anogenital Warts. ISRN Dermatol [Internet] 2012 [cited 2016 Mar 2];2012. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431102
77. Aktaş H, Ergin C, Demir B, Ekiz Ö. Intralvesional Vitamin D injection may be an effective treatment option for warts. J Cutan Med Surg 2016;20:118-22.